Cargando…
Design of the Optimal Trial of Combination Therapy
Patients who take levothyroxine monotherapy to treat hypothyroidism frequently experience residual symptoms despite TSH testing at target levels. Trials have been conducted to evaluate the potential benefit of combination therapy with levothyroxine and liothyronine, though results have not consisten...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146056/ https://www.ncbi.nlm.nih.gov/pubmed/32318021 http://dx.doi.org/10.3389/fendo.2020.00168 |
_version_ | 1783520112647602176 |
---|---|
author | Cappola, Anne R. |
author_facet | Cappola, Anne R. |
author_sort | Cappola, Anne R. |
collection | PubMed |
description | Patients who take levothyroxine monotherapy to treat hypothyroidism frequently experience residual symptoms despite TSH testing at target levels. Trials have been conducted to evaluate the potential benefit of combination therapy with levothyroxine and liothyronine, though results have not consistently demonstrated benefit. In addition to randomization, placebo-control, and masking, four additional design choices to consider include the study population, dosing strategy for levothyroxine and liothyronine, primary and secondary outcome selection, and statistical power. A thoughtful design that considers these features will increase the likelihood that a combination trial will be considered definitive and finally resolve the important question of whether combination therapy with levothyroxine and liothyronine is a better thyroid replacement strategy than levothyroxine monotherapy. |
format | Online Article Text |
id | pubmed-7146056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71460562020-04-21 Design of the Optimal Trial of Combination Therapy Cappola, Anne R. Front Endocrinol (Lausanne) Endocrinology Patients who take levothyroxine monotherapy to treat hypothyroidism frequently experience residual symptoms despite TSH testing at target levels. Trials have been conducted to evaluate the potential benefit of combination therapy with levothyroxine and liothyronine, though results have not consistently demonstrated benefit. In addition to randomization, placebo-control, and masking, four additional design choices to consider include the study population, dosing strategy for levothyroxine and liothyronine, primary and secondary outcome selection, and statistical power. A thoughtful design that considers these features will increase the likelihood that a combination trial will be considered definitive and finally resolve the important question of whether combination therapy with levothyroxine and liothyronine is a better thyroid replacement strategy than levothyroxine monotherapy. Frontiers Media S.A. 2020-04-03 /pmc/articles/PMC7146056/ /pubmed/32318021 http://dx.doi.org/10.3389/fendo.2020.00168 Text en Copyright © 2020 Cappola. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Cappola, Anne R. Design of the Optimal Trial of Combination Therapy |
title | Design of the Optimal Trial of Combination Therapy |
title_full | Design of the Optimal Trial of Combination Therapy |
title_fullStr | Design of the Optimal Trial of Combination Therapy |
title_full_unstemmed | Design of the Optimal Trial of Combination Therapy |
title_short | Design of the Optimal Trial of Combination Therapy |
title_sort | design of the optimal trial of combination therapy |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146056/ https://www.ncbi.nlm.nih.gov/pubmed/32318021 http://dx.doi.org/10.3389/fendo.2020.00168 |
work_keys_str_mv | AT cappolaanner designoftheoptimaltrialofcombinationtherapy |